The U.S. Drug Enforcement Agency plans to reclassify cannabis from a Schedule I drug to Schedule III, acknowledging its medicinal value. Likewise, there’s growing interest in psilocybin for treating conditions like depression and chronic pain. This shift signifies a departure from historically criminalizing these substances, potentially offering alternatives for chronic pain management.
Read the full story here
Written by: FlaglerLive
Published on May 24, 2024 at 11:04AM
Source: FlaglerLive (opens in new tab)